Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Not Yet Opened 08-21 16:00:00 EDT

36.30

-0.54

-1.47%

盘后36.36

+0.06+0.17%

19:51 EDT

High37.18	Low36.23	Vol6.19M
Open37.03	D1 Closing36.84	Amplitude2.59%
Mkt Cap26.22B	Tradable Cap21.09B	Total Shares722.41M
T/O225.49M	T/O Rate1.06%	Tradable Shares581.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":36.3,"timestamp":1787342400000,"preClose":36.84,"halted":0,"volume":6185567,"hourTrading":{"tag":"盘后","latestPrice":36.36,"preClose":36.3,"latestTime":"19:51 EDT","volume":441474,"amount":16025496.6075,"timestamp":1787356304056,"change":0.06,"changeRate":0.001653,"amplitude":0.001653},"delay":0,"changeRate":-0.014657980456026226,"floatShares":581000000,"shares":722406273,"eps":-0.47,"marketStatus":"Not Yet Opened","change":-0.54,"latestTime":"08-21 16:00:00 EDT","open":37.03,"high":37.18,"low":36.225,"amount":225486494.46955,"amplitude":0.025923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.47,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":36.84,"preHourTrading":{"tag":"盘前","latestPrice":37.01,"preClose":36.84,"latestTime":"09:29 EDT","volume":5916,"amount":219403.40861999997,"timestamp":1787318991014,"change":0.17,"changeRate":0.004615,"amplitude":0.105049},"postHourTrading":{"tag":"盘后","latestPrice":36.36,"preClose":36.3,"latestTime":"19:51 EDT","volume":441474,"amount":16025496.6075,"timestamp":1787356304056,"change":0.06,"changeRate":0.001653,"amplitude":0.001653},"volumeRatio":1.1201256134135216,"impliedVol":0.4818,"impliedVolPercentile":0.7769},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"2661213491","title":"Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $12.47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661213491","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661213491?lang=en_us&edition=fundamental","pubTime":"2026-08-22 09:01","pubTimestamp":1787360468,"startTime":"0","endTime":"0","summary":"Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 millionRoivant Sciences President and CIO Mayukh Sukhatme sold 335,174 common shares on Aug. 19-21.Sales priced at USD 36.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260822:nNDL2FCXGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $12.47 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660297413","title":"Roivant President, CIO Mayukh Sukhatme Disposes of USD 24.12 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660297413","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660297413?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:00","pubTimestamp":1787101256,"startTime":"0","endTime":"0","summary":"Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common sharesRoivant Sciences President and CIO Mayukh Sukhatme reported sales of 664,826 common shares on Aug. 14-18.Disposals ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL88FChk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant President, CIO Mayukh Sukhatme Disposes of USD 24.12 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660933564","title":"Roivant Sciences (ROIV) Receives a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2660933564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660933564?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061919,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Roivant Sciences today and set a price target of $42.00. In addition to Jefferies, Roivant Sciences al...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938518","title":"Citi Reaffirms Their Buy Rating on Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938518?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:55","pubTimestamp":1786359346,"startTime":"0","endTime":"0","summary":"In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Roivant Sciences, with a price target of $46.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987522","title":"Roivant Sciences Ltd : Citigroup Raises Target Price to $46 from $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987522?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:15","pubTimestamp":1786356924,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364754","title":"Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364754?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:28","pubTimestamp":1786116505,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00. According to TipRanks, Rah...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-roivant-sciences-roiv-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-roivant-sciences-roiv-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657499136","title":"Roivant Sciences is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657499136","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657499136?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:22","pubTimestamp":1786108920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648299","title":"Roivant Sciences price target raised to $42 from $36 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648299?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:41","pubTimestamp":1786102901,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $36 and keeps a Buy rating on the shares. Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-42-from-36-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-42-from-36-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657718691","title":"Roivant Sciences Ltd : TD Cowen Raises Target Price to $50 from $41","url":"https://stock-news.laohu8.com/highlight/detail?id=2657718691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657718691?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:05","pubTimestamp":1786082707,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4440JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652347","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652347?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:30","pubTimestamp":1786044629,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Opus Genetics (IRD) and Reg...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-283?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-283?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","BK4007","IRD","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632462","title":"Roivant Sciences Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632462","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632462?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023131,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd reports results for the quarter ended June 30 - Earnings SummaryRoivant Sciences LtdROIV.OQreported a quarterly adjusted loss of 26 cents per share for the quarter ended June 30, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632405","title":"Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632405","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632405?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023121,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. reports results for the quarter ended June 30 - Earnings SummaryImmunovant, Inc.IMVT.OQreported a quarterly adjusted loss of 75 cents per share for the quarter ended June 30, lower th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4007","ROIV","BK4585","PTH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139307006","title":"Stock Track | Roivant Sciences Plunges 5.55% in pre-market After Q1 Loss Widens, Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1139307006","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139307006?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:52","pubTimestamp":1786020730,"startTime":"0","endTime":"0","summary":"Shares of Roivant Sciences Ltd. (ROIV) plunged 5.55% in pre-market trading, following the release of the company's fiscal first-quarter results that showed a wider net loss and a decline in...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163591","title":"Roivant Sciences' Fiscal Q1 Net Loss Narrows, Revenue Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163591?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:40","pubTimestamp":1786016421,"startTime":"0","endTime":"0","summary":"Roivant Sciences  reported a fiscal Q1 net loss Thursday of $0.26 per diluted share, narrowing from a loss of $0.33 per share a year earlier.Four analysts polled by FactSet expected a loss of $0.33 per share.Revenue for the quarter ended June 30 was $1.4 million, compared with $2.2 million a year earlier.Analysts expected $2.1 million.Shares of Roivant Sciences were up more than 1% premarket Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV","BK4139","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657335626","title":"Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657335626","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657335626?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015233,"startTime":"0","endTime":"0","summary":"Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 millionImmunovant posted a wider net loss of USD 153.2 million, or USD 0.75 a share, for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnH5Br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ROIV","BK4139","IMVT","PTH","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633894","title":"Earnings Flash (ROIV) Roivant Posts Fiscal Q1 Net Loss $0.26 a Share, vs. FactSet Est of $0.33 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633894","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633894?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:15","pubTimestamp":1786014918,"startTime":"0","endTime":"0","summary":"Earnings Flash (ROIV) Roivant Posts Fiscal Q1 Net Loss $0.26 a Share, vs. FactSet Est of $0.33 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638786","title":"Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638786","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:12","pubTimestamp":1786014730,"startTime":"0","endTime":"0","summary":"Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60988265/roivant-sciences-q1-adj-eps-0-34-misses-0-32-estimate-sales-1-442m-miss-2-057m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657198638","title":"Roivant Unit Priovant Begins Phase 3 Beacon+ Trial of Brepocitinib in Cutaneous Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2657198638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657198638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:07","pubTimestamp":1786014437,"startTime":"0","endTime":"0","summary":"Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosisRoivant unit Priovant enrolled first patients in a Phase 3 trial of brepocitinib for cutaneous sarcoidosis, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL4GgQ86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638191","title":"Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638191","media":"Reuters","labels":["shareholding","policyRegulatory","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638191?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:07","pubTimestamp":1786014430,"startTime":"0","endTime":"0","summary":"Roivant Q1 FY27 net loss widens to $290.61 million; revenue slips to $1.44 millionRoivant posted a GAAP net loss of USD 290.61 million, widening from USD 273.91 million a year earlier; GAAP loss per s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9Ngwhl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PTH","LGHT","BK4533","MRNY","BK4534","MRNA","BK4501","BK4568","BK4548","BK4139","IDNA","GNOM","BK4532","BK4585","MRNX","BK4588","ROIV","BK4551","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638810","title":"Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638810","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638810?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014062,"startTime":"0","endTime":"0","summary":"BRIEF-Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 MillionAug 06  - Roivant Sciences Q1 revenue USD 1.442 million.Q1 net income USD -290.606 millionQ1 pretax profit USD -294.564 million vs. IBES estimate USD -243.7 millionQ1 basic EPS USD -0.26Q1 income from operations USD -365.993 million vs. IBES estimate USD -306.8 millionQ1 operating expenses USD 367.827 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXNPHVMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.2116},{"period":"6month","weight":0.337},{"period":"1year","weight":2.0737},{"period":"ytd","weight":0.6728}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026843},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018688},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}